This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove Heart Valves Remove Innovation Remove Pharmacology
article thumbnail

TRiCares Announces Successful Implantation of Minimally Invasive Topaz Tricuspid Heart Valve Replacement System in Patient with a Pacemaker

DAIC

DECEMBER 22, 2023

Tricuspid regurgitation (TR) is a common and serious disease for which open heart surgery and symptomatic pharmacologic treatment are the current standard treatment options. Owing to high mortality risk, access to open heart surgery is severely restricted and is not considered an option for most patients with TR.

Tricuspid 59
Tricuspid Pacemaker Heart Valves Open-Heart Surgery 59
article thumbnail

Top Interventional Cardiology Conferences and Courses in 2024

Cardiology Update

JANUARY 7, 2024

Fellows 2024 offers hands-on training covering revascularization, angioplasty, stents, pharmacologic therapy, and intravascular imaging/physiology. Noncoronary topics like structural heart disease and vascular medicine are also addressed. The course is relevant for the entire heart valve team.

Interventional Cardiology 64
Interventional Cardiology Innovation Heart Disease Physiology 64
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join thousands of Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024